| Literature DB >> 35565057 |
Dongli Xie1, Jianchen Hu1, Tong Wu2, Kangli Cao3, Xiaogang Luo1.
Abstract
The eye is a superficial organ directly exposed to the surrounding environment. Thus, the toxicity of nanoparticle (NP) pollutants to the eye may be potentially severer relative to inner organs and needs to be monitored. However, the cytotoxic mechanisms of NPs on the eyes remain rarely reported. This study was to screen crucial genes associated with NPs-induced retinal injuries. The gene expression profiles in the retina induced by NPs [GSE49371: Au20, Au100, Si20, Si100; GSE49048: presumptive therapeutic concentration (PTC) TiO2, 10PTC TiO2] and commonly used retinal cell injury models (optic nerve injury procedure: GSE55228, GSE120257 and GSE131486; hypoxia exposure: GSE173233, GSE151610, GSE135844; H2O2 exposure: GSE122270) were obtained from the Gene Expression Omnibus database. A total of 381 differentially expressed genes (including 372 mRNAs and 9 lncRNAs) were shared between NP exposure and the optic nerve injury model when they were compared with their corresponding controls. Function enrichment analysis of these overlapped genes showed that Tlr2, Crhbp, Ccl2, Cxcl10, Fas, Irf8, Socs3, Stat3, Gbp6, Casp1 and Syk were involved in inflammatory- and apoptotic-related processes. Protein-protein interaction network analysis revealed eight of them (Tlr2, Ccl2, Cxcl10, Irf8, Socs3, Stat3, Casp1 and Syk) were hub genes. Moreover, Socs3 could interact with upstream Stat3 and downstream Fas/Casp1/Ccl2/Cxcl10; Irf8 could interact with upstream Tlr2, Syk and downstream Cxcl10. Competing endogenous RNAs network analysis identified Socs3, Irf8, Gdf6 and Crhbp could be regulated by lncRNAs and miRNAs (9330175E14Rik-mmu-miR-762-Socs3, 6430562O15Rik-mmu-miR-207-Irf8, Gm9866-mmu-miR-669b-5p-Gdf6, 4933406C10Rik-mmu-miR-9-5p-Crhbp). CMap-CTD database analyses indicated the expression levels of Tlr2, Ccl2, Cxcl10, Fas, Irf8, Socs3, Stat3, Gbp6, Casp1 and Syk could be reversed by folic acid. Crhbp and Gdf6 were also verified to be downregulated, while Tlr2, Ccl2, Irf8, Socs3 and Stat3 were upregulated in hypoxia/H2O2-induced retinal injury models. Hereby, our findings suggest that Crhbp, Irf8, Socs3 and Gdf6 as well as their upstream mRNAs, lncRNAs and miRNAs may be potential monitoring biomarkers and therapeutic targets for NP-induced retinal injuries. Folic acid supplementation may be a preventive and therapeutic approach.Entities:
Keywords: apoptosis; competing endogenous RNAs; inflammation; long non-coding RNAs; nanoparticles; retinal injury
Mesh:
Substances:
Year: 2022 PMID: 35565057 PMCID: PMC9099825 DOI: 10.3390/ijerph19095664
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Figure 1Identification of differentially expressed RNAs. (A) a volcano plot to show the differentially expressed RNAs of the GSE49048 dataset with PTC TiO2 NP exposure; (B) a volcano plot to show the differentially expressed RNAs of the GSE49048 dataset with 10PTC TiO2 NP exposure; (C) a volcano plot to show the differentially expressed RNAs of the GSE49371 dataset with Au20 NP exposure; (D) a volcano plot to show the differentially expressed RNAs of the GSE49371 dataset with Au100 NP exposure; (E) a volcano plot to show the differentially expressed RNAs of the GSE49371 dataset with Si20 NP exposure; (F) a volcano plot to show the differentially expressed RNAs of the GSE49371 dataset with Au100 NP exposure; (G) a heat map to show the differentially expressed RNAs of the GSE55228 dataset undergoing ONC procedures; (H), a heat map to show the differentially expressed RNAs of the GSE120257 dataset undergoing ONC procedures; (I) a heat map to show the differentially expressed RNAs of the GSE131486 dataset undergoing ONC procedures. Blue dots in the volcano plots are downregulated genes; red dots in the volcano plots are upregulated genes; blue in the heatmap indicates high expressed genes; red in the heatmap indicates low expressed genes; FC, fold change; ONC, optic nerve crush; PTC: presumptive therapeutic concentration; NPs: nanoparticles; Ag: silver; Au: gold; Si: silicate.
Figure 2Venn diagrams to show the overlapped genes between NP exposure and ONC treatment. (A) overlapped upregulated genes between PTC TiO2 NPs of GSE49048 and GSE55228-GSE120257-GSE131486; (B) downregulated upregulated genes between PTC TiO2 NPs of GSE49048 and GSE55228-GSE120257-GSE131486; (C) overlapped upregulated genes between 10PTC TiO2 NPs of GSE49048 and GSE55228-GSE120257-GSE131486; (D) overlapped downregulated genes between 10PTC TiO2 NPs of GSE49048 and GSE55228-GSE120257-GSE131486; (E) overlapped upregulated genes between Au20 NPs of GSE49371 and GSE55228-GSE120257-GSE131486; (F) overlapped downregulated genes between Au20 NPs of GSE49371 and GSE55228-GSE120257-GSE131486; (G) overlapped upregulated genes between Au100 NPs of GSE49371 and GSE55228-GSE120257-GSE131486; (H) overlapped downregulated genes between Au100 NPs of GSE49371 and GSE55228-GSE120257-GSE131486; (I) overlapped upregulated genes between Si20 NPs of GSE49371 and GSE55228-GSE120257-GSE131486; (J) overlapped downregulated genes between Si20 NPs of GSE49371 and GSE55228-GSE120257-GSE131486; (K) overlapped upregulated genes between Si100 NPs of GSE49371 and GSE55228-GSE120257-GSE131486; (L) overlapped downregulated genes between Si100 NPs of GSE49371 and GSE55228-GSE120257-GSE131486. PTC: presumptive therapeutic concentration; NPs: nanoparticles; Ag: silver; Au: gold; Si: silicate.
Crucial genes changed by nanoparticles to induce the retinal injury.
| Treatment | Gene Symbol | GSE49048 | GSE55228 | GSE120257 | GSE131486 | ||||
|---|---|---|---|---|---|---|---|---|---|
| Log2FC | Log2FC | Log2FC | Log2FC | ||||||
| TiO2 vs. control (PTC) | Gm9866 | −0.50 | 3.94 × 102 | −0.57 | 2.74 × 102 | ||||
|
| 1.44 | 3.97 × 102 | 0.85 | 6.09 × 1013 | 0.62 | 1.47 × 102 | |||
|
| 1.00 | 2.98 × 102 | 1.04 | 4.73 × 1051 | 0.63 | 2.83 × 102 | |||
|
| 1.35 | 4.44 × 102 | 0.78 | 1.90 × 106 | |||||
|
| 0.65 | 3.49 × 102 | 0.91 | 4.91 × 1011 | |||||
| TiO2 vs. control (100 PTC) | 6430562O15Rik | 0.54 | 1.32 × 103 | 0.77 | 1.04 × 107 | ||||
| 9330175E14Rik | 1.24 | 3.92 × 102 | 0.62 | 3.30 × 106 | |||||
|
| 1.08 | 1.60 × 103 | 2.38 | 1.55 × 103 | 1.14 | 3.06 × 1012 | 1.54 | 4.20 × 102 | |
|
| 1.44 | 1.59 × 103 | 0.64 | 5.26 × 103 | 1.73 | 5.75 × 1051 | |||
|
| 1.16 | 4.06 × 103 | 0.85 | 6.09 × 1013 | 0.62 | 1.47 × 102 | |||
|
| 0.66 | 2.83 × 102 | 1.25 | 5.84 × 1030 | 0.57 | 1.01 × 102 | |||
|
| 1.39 | 6.97 × 104 | 1.05 | 3.01 × 1013 | 1.07 | 4.07 × 103 | |||
|
| 2.43 | 8.73 × 103 | 1.39 | 4.11 × 1018 | 1.90 | 1.31 × 102 | |||
|
| 1.36 | 1.3 × 104 | 1.61 | 3.81 × 1038 | 1.08 | 2.43 × 102 | |||
|
| 1.60 | 3.24 × 103 | 5.63 | 7.48 × 103 | |||||
|
| 1.03 | 9.11 × 104 | 1.04 | 4.73 × 1051 | 0.63 | 2.83 × 102 | |||
|
| 0.91 | 1.10× 102 | 0.73 | 7.64 × 104 | |||||
|
| 1.17 | 8.88 × 103 | 0.78 | 1.90 × 106 | |||||
|
| 1.00 | 9.77 × 103 | 0.70 | 1.63 × 105 | |||||
|
| 1.19 | 3.2 × 104 | 0.56 | 7.35 × 105 | |||||
|
| 0.61 | 1.37 × 103 | 0.91 | 4.91 × 1011 | |||||
|
| −0.62 | 1.00× 102 | −0.70 | 2.27 × 107 | −1.50 | 3.19 × 1055 | −1.48 | 1.78 × 1010 | |
| Au20 vs. control | 4933406C10Rik | 0.73 | 3.32× 102 | 0.96 | 9.35 × 103 | ||||
|
| 1.22 | 4.29× 102 | 0.61 | 2.44 × 102 | |||||
|
| −0.98 | 1.20 × 103 | −1.14 | 4.97 × 102 | |||||
| Au100 vs. control | 4933406C10Rik | 0.74 | 385× 102 | 0.96 | 9.35 × 103 | ||||
|
| 2.10 | 3.40× 102 | 0.61 | 2.44 × 102 | |||||
| D030047H15Rik | 0.56 | 5.06 × 103 | 0.87 | 2.08 × 102 | |||||
| Si20 vs. control | 4933406C10Rik | 0.61 | 1.60× 102 | 0.96 | 9.35 × 103 | ||||
|
| 1.74 | 2.73× 102 | 0.61 | 2.44 × 102 | |||||
FC: fold change; PTC: presumptive therapeutic concentration; TiO2: titanium dioxide; Au20: gold with diameters of 20 nm; Au100: gold with diameters of 100 nm; Si20: silicate with diameters of 20 nm; Si100: silicate with diameters of 100 nm.
Figure 3Function enrichment for the overlapped differentially expressed mRNAs between GSE49048-GSE49371 and GSE55228-GSE120257-GSE131486 datasets. (A) GO term; (B) KEGG pathways. Only top 20 are shown. GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes.
GO term enrichment results.
| Term | Genes | |
|---|---|---|
| GO:0002376~immune system process | 3.04 × 1027 | IFITM3, H2-T23, SPON2, CD84, CSF1, H2-K1, AHR, IFI30, IFIT1, IFIT3, IFIH1, MAP3K8, LGALS9, JAK3, B2M, OASL2, HERC6, RSAD2, SYK, DDX58, TAP1, FCGR1, NAIP2, HCK, IRF1, SERPING1, H2-D1, TLR13, TLR2, TRIM56, C1QB, C1QA, UNC93B1, H2-Q7, NLRC5, ZC3HAV1, INPP5D, C1RA, LY86, EIF2AK2, IRGM1, PSMB8, PSMB9, BST2, BCL6, AXL, MYO1G, C1QC |
| GO:0045087~innate immune response | 7.54 × 1022 | IFITM3, C1QB, SPON2, C1QA, CD84, CSF1, UNC93B1, NLRC5, OAS1A, TREM2, ZC3HAV1, IFIT1, IFIT3, IFIH1, C4B, CLEC7A, JAK3, TRIM21, B2M, HERC6, OASL2, C1RA, FCER1G, RSAD2, SYK, DDX58, LY86, CYBB, IRGM1, EIF2AK2, CYBA, BST2, FCGR1, NAIP2, HCK, TYROBP, AXL, IRF1, SERPING1, TLR13, TLR2, C1QC, TRIM56 |
| GO:0006954~inflammatory response | 5.15 × 1014 | PTGFR, CCL12, CALCA, CXCL9, NCF1, CSF1, CXCL1, AIF1, PTGS1, C4B, CRHBP, CLEC7A, STAB1, SPP1, CCL3, C3AR1, CCL2, SLC11A1, LY86, CYBB, CYBA, TNFRSF1B, TNFRSF1A, P2RX7, CXCL10, NAIP2, HCK, BCL6, TNIP2, AXL, FAS, TLR13, TLR2 |
| GO:0051607~defense response to virus | 5.61 × 1014 | APOBEC1, IFITM3, SPON2, CXCL9, RSAD2, UNC93B1, DDX58, NLRC5, EIF2AK2, OAS1A, ZC3HAV1, DDX60, IFIT1, IFIT3, IFIH1, BST2, CXCL10, IRF1, ITGAX, PMAIP1, TRIM56, OASL2 |
| GO:0009615~response to virus | 2.52 × 1012 | IFITM3, RSAD2, DDX58, EIF2AK2, OAS1A, ZC3HAV1, DDX60, IFIT1, IFIT3, IFIH1, BST2, CXCL10, BCL3, TLR13, OASL2 |
| GO:0035458~cellular response to interferon-beta | 2.65 × 109 | GBP6, IFI204, IRF1, IFI203, IGTP, IRGM2, IRGM1, IFIT1, GBP2, IFIT3, GBP3 |
| GO:0032496~response to lipopolysaccharide | 4.44 × 109 | SPON2, PTGFR, CEBPB, CXCL9, GCH1, SLC11A1, EIF2AK2, CXCL1, TNFRSF1B, LITAF, TNFRSF1A, P2RX7, CXCL10, CASP8, PENK, CASP1, ACP5, FAS, LGALS9, TLR2 |
| GO:0050830~defense response to Gram-positive bacterium | 1.53 × 108 | GBP6, H2-T23, GBP7, NCF1, GBP9, LYZ2, P2RX7, HCK, ACP5, GBP2, B2M, MYO1F, TLR2, GBP3 |
| GO:0042832~defense response to protozoan | 5.00 × 108 | GBP6, GBP7, GBP9, SLC11A1, BCL3, IRGM2, IRF8, GBP2, GBP3 |
| GO:0071222~cellular response to lipopolysaccharide | 6.62 × 108 | CX3CR1, GBP6, SPON2, CEBPB, ARG1, SERPINE1, TNFRSF1B, LITAF, ICAM1, CXCL10, SBNO2, PLSCR2, FCGR4, TNIP2, AXL, CCL2, IRF8, GBP2, B2M |
| GO:0006955~immune response | 1.68 × 107 | CCL12, CXCL9, H2-K1, LIF, CXCL1, TNFRSF1B, CTSS, VAV1, TNFRSF1A, CXCL10, BLNK, CCL3, CCL2, FAS, IRF8, LCP2, FCGR2B, B2M, H2-D1, TLR2, OASL2 |
| GO:0044406~adhesion of symbiont to host | 2.44 × 107 | GBP6, GBP7, GBP9, GBP2, ICAM1, GBP3 |
| GO:0071346~cellular response to interferon-gamma | 4.42 × 107 | GBP6, CCL12, GBP7, GBP9, H2-Q7, CCL3, CCL2, GBP2, AIF1, GBP4, GBP3 |
| GO:0030593~neutrophil chemotaxis | 5.09 × 107 | FCGR3, CCL12, EDN2, FCER1G, SYK, SPP1, CCL3, CCL2, CXCL1, NCKAP1L, VAV1 |
| GO:0042742~defense response to bacterium | 5.22 × 107 | SPON2, CEBPB, FCER1G, SYK, NCF1, ANXA3, LYZ2, SLC11A1, H2-M3, H2-K1, IRGM2, TNFRSF1A, FCGR1, NAIP2, BCL3, STAB1, IRF8 |
| GO:0042590~antigen processing and presentation of exogenous peptide antigen via MHC class I | 5.57 × 107 | FCGR1, FCGR3, FCER1G, H2-K1, IFI30 |
| GO:0032760~positive regulation of tumor necrosis factor production | 1.22 × 106 | SASH3, H2-T23, SPON2, FCER1G, CCL3, CCL2, CYBA, LGALS9, TNFRSF1A, TLR2 |
| GO:0009617~response to bacterium | 2.91 × 106 | FCGR1, P2RX7, NCF1, SLC11A1, CASP1, IRF8, FCGR2B, TLR2 |
| GO:0002474~antigen processing and presentation of peptide antigen via MHC class I | 3.56 × 106 | H2-T23, H2-BL, H2-Q6, H2-Q7, H2-K1, H2-M3, B2M, H2-D1 |
| GO:0006935~chemotaxis | 1.16 × 105 | CX3CR1, CXCL10, CXCL9, CCL12, RAC2, C3AR1, CCL3, CCL2, NCKAP1L, LGALS9, DOCK2, CYR61 |
| GO:0002479~antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent | 1.52 × 105 | H2-T23, H2-Q7, H2-K1, B2M, PSMB8, H2-D1, PSMB9 |
| GO:0019221~cytokine-mediated signaling pathway | 1.69 × 105 | CX3CR1, CCL12, EDN2, STAT3, CSF2RB, TNFRSF1A, CSF2RB2, SOCS3, CCL2, PTPN6, IL6ST, JAK3, CD44 |
| GO:0010628~positive regulation of gene expression | 1.75 × 105 | PTGFR, CSF1, DDX58, SLC11A1, SERPINE1, STAT3, PLAUR, LIF, SOX11, IKZF1, POU4F1, FGF2, TNFRSF1A, P2RX7, CCL3, CTSH, VIM, LGALS9, ATF3, CD44, NKX3-1, TLR2 |
| GO:0001916~positive regulation of T cell mediated cytotoxicity | 1.93 × 105 | P2RX7, H2-T23, H2-K1, H2-M3, B2M, H2-D1 |
| GO:0050766~positive regulation of phagocytosis | 2.60 × 105 | FCGR1, FCGR3, FCER1G, PROS1, SLC11A1, CYBA, DOCK2, FCGR2B |
| GO:0009636~response to toxic substance | 2.89 × 105 | CDKN1A, PENK, CCL3, EIF2AK2, FAS, NEFL, AHR, NUPR1, SLC7A11, TLR2 |
| GO:0007155~cell adhesion | 3.58 × 105 | CX3CR1, LGALS3BP, SPON2, CD84, VWF, CD93, TNFAIP6, TNFRSF12A, FBLIM1, MCAM, PCDH8, CYR61, ICAM1, MFAP4, GPNMB, CHL1, PDPN, STAB1, SPP1, ITGAX, CD9, CTNNAL1, CD33, CD44 |
| GO:0006909~phagocytosis | 4.43 × 105 | HCK, ANXA3, AXL, SLC11A1, PLD4, IRF8, VAV1, MYO1G |
| GO:0045576~mast cell activation | 7.08 × 105 | FCGR3, FCER1G, LCP2, CD48, FCGR2B |
| GO:0048246~macrophage chemotaxis | 9.77 × 105 | CX3CR1, CCL12, EDN2, CCL3, CCL2 |
| GO:0034341~response to interferon-gamma | 9.84 × 105 | IFITM3, BST2, GCH1, SLC11A1, IRGM2, TRIM21 |
| GO:0030335~positive regulation of cell migration | 1.04 × 104 | TNFAIP6, CSF1, SEMA3C, MCAM, AIF1, CYR61, CXCL10, GPNMB, PDPN, C3AR1, CCL3, CTSH, ROR2, MYO1F |
| GO:0050729~positive regulation of inflammatory response | 1.54 × 104 | CCL12, SERPINE1, CCL3, CCL2, CTSS, TNFRSF1A, TLR2, TGM2 |
| GO:0045730~respiratory burst | 2.05 × 104 | NCF1, SLC11A1, CYBB, CYBA |
| GO:0043029~T cell homeostasis | 2.36 × 104 | P2RX7, PMAIP1, FAS, NCKAP1L, AHR, JAK3 |
| GO:0042771~intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 2.36 × 104 | CDKN1A, IFI204, BCL3, SHISA5, PMAIP1, NUPR1 |
| GO:0045071~negative regulation of viral genome replication | 2.75 × 104 | IFITM3, BST2, RSAD2, EIF2AK2, ZC3HAV1 |
| GO:0008285~negative regulation of cell proliferation | 2.92 × 104 | IFITM3, CDKN1A, IGFBP3, STAT3, LIF, EIF2AK2, DHCR24, FGF2, IFIT3, MYO16, RUNX1, BCL6, IRF1, INPP5D, CD9, ROR2, NKX3-1, SKAP2, TLR2 |
| GO:0043615~astrocyte cell migration | 3.24 × 104 | CCL12, HEXB, CCL3, CCL2 |
| GO:0007568~aging | 3.72 × 104 | CALCA, ARG1, STAT3, PENK, SERPING1, CCL2, APOD, TIMP1, TNFRSF1B, LITAF, FGF2, CTSC |
| GO:0071407~cellular response to organic cyclic compound | 4.58 × 104 | P2RX7, MSR1, CEBPB, CCL12, CASP8, STAT3, CCL3, CYBA |
| GO:0071347~cellular response to interleukin-1 | 6.78 × 104 | CEBPB, CCL12, IRF1, SERPINE1, CCL3, CCL2, ICAM1, NKX3-1 |
| GO:0030168~platelet activation | 7.08 × 104 | ENTPD1, VWF, SYK, AXL, ADRA2C, VAV1 |
| GO:0045944~positive regulation of transcription from RNA polymerase II promoter | 8.08 × 104 | CSRNP1, CEBPB, CEBPD, HEXB, NLRC5, IKZF1, FGF2, CYR61, SBNO2, CCL3, JAK3, ZBTB7C, NKX3-1, WWTR1, EGR2, DDX58, SLC11A1, STAT3, ARID5A, LIF, SOX11, POU4F1, POU4F2, RUNX1, TNFRSF1A, HOXB9, TNIP2, IRF1, BCL3, CAPRIN2, FOSB, ATF3, TLR2, CREB5 |
| GO:0043066~negative regulation of apoptotic process | 8.49 × 104 | PTGFR, CDKN1A, STAT3, PLAUR, EIF2AK2, DHCR24, AIF1, POU4F1, CYR61, IFIT3, TNFRSF1A, BTC, HCK, SOCS3, BCL6, AXL, BCL3, SPP1, CTSH, FAS, NCKAP1L, TIMP1, CD44 |
| GO:0008217~regulation of blood pressure | 9.63 × 104 | CALCA, EDN2, GCH1, C3AR1, CYBA, AHR, PTGS1 |
| GO:0071356~cellular response to tumor necrosis factor | 9.78 × 104 | CRHBP, CCL12, CALCA, IRF1, CCL3, CCL2, CYBA, ICAM1, NKX3-1 |
| GO:0035457~cellular response to interferon-alpha | 1.20 × 103 | IFI204, AXL, IFIT1, IFIT3 |
| GO:0043065~positive regulation of apoptotic process | 1.45 × 103 | HRK, TNFRSF12A, GADD45B, IGFBP3, EIF2AK2, POU4F1, CYR61, P2RX7, CASP8, BCL6, INPP5D, CASP1, PMAIP1, FAS, NUPR1, TGM2 |
| GO:0097191~extrinsic apoptotic signaling pathway | 6.69 × 103 | P2RX7, CASP8, TNFRSF12A, FAS, TNFRSF1B |
| GO:0006915~apoptotic process | 9.46 × 103 | HRK, CSRNP1, TNFRSF12A, NCF1, GADD45B, SHISA5, GDF6, LITAF, TNFRSF1A, RNF144B, NAIP2, CASP8, TNIP2, IRF1, INPP5D, CASP1, PMAIP1, FAS, MAP3K8, XAF1 |
| GO:0042127~regulation of cell proliferation | 9.50 × 103 | APOBEC1, CXCL10, HCK, CXCL9, BCL6, SERPINE1, TCF7, FAS, TNFRSF1B, TNFRSF1A, PTGS1 |
| GO:0042981~regulation of apoptotic process | 1.16 × 102 | HRK, CASP8, BCL3, CASP1, PMAIP1, EIF2AK2, FAS, TNFRSF1B, GDF6, TNFRSF1A |
| GO:0048678~response to axon injury | 2.07 × 102 | ARG1, APOD, FGF2, AIF1 |
| GO:0043524~negative regulation of neuron apoptotic process | 2.89 × 102 | CEBPB, CCL12, CHL1, AXL, NEFL, CCL2, POU4F1, NES |
GO: Gene Ontology. Only results with false discovery rate < 0.05 and apoptosis-related processes are listed.
KEGG pathway enrichment results.
| Term | Genes | |
|---|---|---|
| mmu04380:Osteoclast differentiation | 3.44 × 109 | SYK, NCF1, CSF1, CYBB, CYBA, TREM2, TNFRSF1A, FCGR1, SOCS3, FCGR3, TYROBP, FCGR4, BLNK, ACP5, FOSB, LCP2, FCGR2B, IRF9 |
| mmu04145:Phagosome | 1.08 × 108 | H2-T23, MSR1, C1RA, H2-BL, NCF1, H2-Q6, H2-Q7, H2-M3, H2-K1, TAP1, CYBA, CTSS, FCGR1, FCGR3, CLEC7A, TUBB3, FCGR4, FCGR2B, H2-D1, TLR2 |
| mmu04668:TNF signaling pathway | 2.29 × 108 | CEBPB, CCL12, CSF1, LIF, CXCL1, TNFRSF1B, TNFRSF1A, ICAM1, CXCL10, SOCS3, CASP8, BCL3, CCL2, FAS, MAP3K8, CREB5 |
| mmu05168:Herpes simplex infection | 5.17 × 108 | H2-T23, CCL12, H2-BL, DDX58, H2-Q6, H2-Q7, H2-M3, H2-K1, EIF2AK2, OAS1A, TAP1, IFIT1, TNFRSF1A, IFIH1, SOCS3, CASP8, CCL2, FAS, IRF9, H2-D1, TLR2 |
| mmu05169:Epstein-Barr virus infection | 7.42 × 108 | H2-T23, ENTPD1, CDKN1A, H2-BL, SYK, DDX58, H2-Q6, H2-Q7, H2-M3, STAT3, H2-K1, EIF2AK2, ICAM1, VIM, JAK3, H2-D1, CD44 |
| mmu04610:Complement and coagulation cascades | 1.31 × 107 | C1QB, C1QA, C1RA, VWF, PROS1, SERPINE1, PLAUR, PLAT, C4B, C3AR1, SERPING1, A2M, C1QC |
| mmu05150:Staphylococcus aureus infection | 1.50 × 107 | FCGR1, C1QB, C4B, C1QA, FCGR3, C1RA, FCGR4, C3AR1, FCGR2B, ICAM1, C1QC |
| mmu04612:Antigen processing and presentation | 1.65 × 105 | H2-T23, H2-BL, H2-Q6, H2-Q7, H2-K1, H2-M3, TAP1, IFI30, B2M, CTSS, H2-D1 |
| mmu05203:Viral carcinogenesis | 2.12 × 105 | H2-T23, EGR2, CDKN1A, H2-BL, SYK, H2-Q6, H2-Q7, H2-M3, STAT3, H2-K1, EIF2AK2, CASP8, PMAIP1, IL6ST, JAK3, IRF9, H2-D1, CREB5 |
| mmu05142:Chagas disease (American trypanosomiasis) | 2.23 × 105 | C1QB, GNA14, C1QA, CCL12, CASP8, SERPINE1, CCL3, FAS, CCL2, TNFRSF1A, C1QC, TLR2 |
| mmu05164:Influenza A | 3.64 × 105 | CCL12, RSAD2, DDX58, MX2, EIF2AK2, OAS1A, TNFRSF1A, ICAM1, IFIH1, CXCL10, SOCS3, CASP1, CCL2, FAS, IRF9 |
| mmu04060:Cytokine-cytokine receptor interaction | 3.86 × 105 | CX3CR1, IL15RA, CCL12, CXCL9, TNFRSF12A, CSF1, LIF, CXCL1, CSF2RB, OSMR, TNFRSF1B, TNFRSF1A, CSF2RB2, CXCL10, CCL3, CCL2, FAS, IL6ST |
| mmu05416:Viral myocarditis | 7.61 × 105 | H2-T23, CASP8, H2-BL, H2-Q6, H2-Q7, H2-K1, H2-M3, RAC2, H2-D1, ICAM1 |
| mmu04666:Fc gamma R-mediated phagocytosis | 1.23 × 104 | FCGR1, HCK, NCF1, SYK, MYO10, INPP5D, RAC2, DOCK2, FCGR2B, VAV1 |
| mmu04650:Natural killer cell mediated cytotoxicity | 1.41 × 104 | TYROBP, FCER1G, SYK, FCGR4, RAC2, FAS, PTPN6, LCP2, CD48, VAV1, ICAM1 |
| mmu04062:Chemokine signaling pathway | 1.60 × 104 | CX3CR1, CCL12, CXCL9, NCF1, STAT3, CXCL1, VAV1, CXCL10, HCK, CCL3, RAC2, GNB3, CCL2, DOCK2, JAK3 |
| mmu05332:Graft-versus-host disease | 1.69 × 104 | H2-T23, H2-BL, H2-Q6, H2-Q7, H2-K1, H2-M3, FAS, H2-D1 |
| mmu05330:Allograft rejection | 2.72 × 104 | H2-T23, H2-BL, H2-Q6, H2-Q7, H2-K1, H2-M3, FAS, H2-D1 |
| mmu05133:Pertussis | 2.77 × 104 | C1QB, C4B, C1QA, C1RA, IRF1, CASP1, SERPING1, IRF8, C1QC |
| mmu04940:Type I diabetes mellitus | 5.14 × 104 | H2-T23, H2-BL, H2-Q6, H2-Q7, H2-K1, H2-M3, FAS, H2-D1 |
| mmu05152:Tuberculosis | 7.21 × 104 | CEBPB, FCER1G, SYK, CTSS, TNFRSF1A, FCGR1, FCGR3, CASP8, CLEC7A, FCGR4, ITGAX, FCGR2B, TLR2 |
| mmu05144:Malaria | 7.51 × 104 | CCL12, CCL2, HBB-B1, HBA-A2, HBA-A1, ICAM1, TLR2 |
| mmu04115:p53 signaling pathway | 8.25 × 104 | CDKN1A, CASP8, GADD45B, IGFBP3, SERPINE1, SHISA5, PMAIP1, FAS |
| mmu04662:B cell receptor signaling pathway | 1.07 × 103 | CD72, SYK, INPP5D, BLNK, RAC2, PTPN6, FCGR2B, VAV1 |
| mmu05162:Measles | 1.13 × 103 | IFIH1, DDX58, MX2, STAT3, EIF2AK2, FAS, OAS1A, FCGR2B, JAK3, IRF9, TLR2 |
| mmu05320:Autoimmune thyroid disease | 1.17 × 103 | H2-T23, H2-BL, H2-Q6, H2-Q7, H2-K1, H2-M3, FAS, H2-D1 |
| mmu04630:Jak-STAT signaling pathway | 1.83 × 103 | CSF2RB2, IL15RA, SOCS3, STAT3, LIF, PTPN6, CSF2RB, IL6ST, OSMR, JAK3, IRF9 |
| mmu05140:Leishmaniasis | 3.39 × 103 | FCGR1, FCGR3, NCF1, FCGR4, CYBA, PTPN6, TLR2 |
| mmu05160:Hepatitis C | 4.04 × 103 | SOCS3, CDKN1A, DDX58, IRF1, STAT3, EIF2AK2, OAS1A, IFIT1, IRF9, TNFRSF1A |
| mmu04142:Lysosome | 6.97 × 103 | HEXB, SLC11A1, LAPTM5, ACP5, CTSH, CD68, LITAF, CTSS, CTSC |
| mmu05143:African trypanosomiasis | 8.14 × 103 | FAS, HBB-B1, HBA-A2, HBA-A1, ICAM1 |
| mmu04621:NOD-like receptor signaling pathway | 9.72 × 103 | NAIP2, CCL12, CASP8, CASP1, CCL2, CXCL1 |
| mmu05166:HTLV-I infection | 1.10 × 102 | H2-T23, IL15RA, EGR2, CDKN1A, H2-BL, H2-Q6, H2-Q7, H2-M3, H2-K1, TNFRSF1A, ICAM1, JAK3, ATF3, H2-D1 |
| mmu05323:Rheumatoid arthritis | 1.13 × 102 | CCL12, CSF1, CCL3, CCL2, ACP5, ICAM1, TLR2 |
| mmu05161:Hepatitis B | 1.92 × 102 | IFIH1, EGR2, CDKN1A, CASP8, DDX58, STAT3, FAS, CREB5, TLR2 |
| mmu04664:Fc epsilon RI signaling pathway | 1.98 × 102 | FCER1G, SYK, INPP5D, RAC2, LCP2, VAV1 |
| mmu04620:Toll-like receptor signaling pathway | 2.87 × 102 | CXCL10, CXCL9, CASP8, SPP1, CCL3, MAP3K8, TLR2 |
| mmu04611:Platelet activation | 3.12 × 102 | FCER1G, VWF, SYK, COL5A2, TBXAS1, PRKG2, LCP2, PTGS1 |
| mmu05134:Legionellosis | 4.17 × 102 | NAIP2, CASP8, CASP1, CXCL1, TLR2 |
| mmu04210:Apoptosis | 4.88 × 102 | CSF2RB2, CASP8, FAS, CSF2RB, TNFRSF1A |
KEGG: Kyoto Encyclopedia of Genes and Genomes.
Hub genes identified by topological characteristics.
| Genes | DC | Genes | EC | Genes | LAC | Genes | BC | Genes | CC |
|---|---|---|---|---|---|---|---|---|---|
|
| 77 |
| 0.16 |
| 28.38 |
| 6332.91 |
| 0.044 |
|
| 73 |
| 0.16 |
| 28.13 |
| 5426.13 |
| 0.044 |
|
| 70 |
| 0.16 |
| 27.79 |
| 4681.39 |
| 0.043 |
|
| 66 |
| 0.16 |
| 27.67 |
| 4583.62 |
| 0.043 |
|
| 64 |
| 0.15 |
| 27.58 |
| 4057.10 |
| 0.043 |
|
| 62 |
| 0.15 |
| 27.47 |
| 3852.56 |
| 0.043 |
|
| 60 |
| 0.14 |
| 27.46 |
| 3484.15 |
| 0.043 |
|
| 60 |
| 0.14 |
| 27.11 |
| 3158.54 |
| 0.043 |
|
| 58 |
| 0.14 |
| 26.92 |
| 3102.06 |
| 0.043 |
|
| 57 |
| 0.13 |
| 26.69 |
| 2981.26 |
| 0.043 |
|
| 55 |
| 0.13 |
| 26.37 |
| 2352.07 |
| 0.043 |
|
| 55 |
| 0.13 |
| 26.27 |
| 2348.79 |
| 0.043 |
|
| 55 |
| 0.13 |
| 26.15 |
| 2238 |
| 0.043 |
|
| 54 |
| 0.13 |
| 26 |
| 2238 |
| 0.043 |
|
| 54 |
| 0.12 |
| 25.94 |
| 2156.60 |
| 0.043 |
|
| 54 |
| 0.12 |
| 25.89 |
| 2130.30 |
| 0.043 |
|
| 54 |
| 0.12 |
| 25.83 |
| 2039.41 |
| 0.043 |
|
| 54 |
| 0.12 |
| 25.48 |
| 1996.1 |
| 0.043 |
|
| 50 |
| 0.12 |
| 25.44 |
| 1920.96 |
| 0.043 |
|
| 48 |
| 0.12 |
| 25.32 |
| 1830.66 |
| 0.043 |
|
| 47 |
| 0.12 |
| 25.30 |
| 1772.68 |
| 0.043 |
|
| 47 |
| 0.11 |
| 25.24 |
| 1763.02 |
| 0.043 |
|
| 47 |
| 0.11 |
| 25.15 |
| 1704.59 |
| 0.043 |
|
| 47 |
| 0.11 |
| 25.08 |
| 1680 |
| 0.043 |
|
| 46 |
| 0.11 |
| 24.80 |
| 1619.14 |
| 0.043 |
|
| 46 |
| 0.11 |
| 24.77 |
| 1564.14 |
| 0.043 |
|
| 46 |
| 0.11 |
| 24.59 |
| 1519.08 |
| 0.043 |
|
| 46 |
| 0.11 |
| 24.24 |
| 1491.62 |
| 0.043 |
|
| 45 |
| 0.11 |
| 24.23 |
| 1475.19 |
| 0.043 |
|
| 45 |
| 0.11 |
| 24.23 |
| 1474.78 |
| 0.043 |
|
| 45 |
| 0.11 |
| 23.6 |
| 1448.63 |
| 0.043 |
|
| 44 |
| 0.11 |
| 23.56 |
| 1429.51 |
| 0.043 |
|
| 44 |
| 0.101 |
| 23.52 |
| 1427.96 |
| 0.043 |
|
| 44 |
| 0.101 |
| 23.36 |
| 1422.19 |
| 0.043 |
|
| 43 |
| 0.101 |
| 23.33 |
| 1404.39 |
| 0.043 |
|
| 43 |
| 0.101 |
| 23.22 |
| 1373.28 |
| 0.043 |
|
| 43 |
| 0.101 |
| 22.90 |
| 1337.92 |
| 0.043 |
|
| 43 |
| 0.10 |
| 22.85 |
| 1322.43 |
| 0.043 |
|
| 43 |
| 0.10 |
| 22.70 |
| 1297.18 |
| 0.043 |
|
| 43 |
| 0.10 |
| 22.60 |
| 1273.40 |
| 0.043 |
|
| 42 |
| 0.10 |
| 22.52 |
| 1255.33 |
| 0.043 |
|
| 42 |
| 0.10 |
| 22.4 |
| 1219.90 |
| 0.043 |
|
| 42 |
| 0.09 |
| 22 |
| 1208.70 |
| 0.043 |
|
| 42 |
| 0.09 |
| 21.68 |
| 1202.51 |
| 0.043 |
|
| 41 |
| 0.09 |
| 21.67 |
| 1200.55 |
| 0.043 |
|
| 41 |
| 0.09 |
| 21.56 |
| 1195.79 |
| 0.043 |
|
| 40 |
| 0.09 |
| 21.44 |
| 1156.12 |
| 0.043 |
|
| 40 |
| 0.09 |
| 21.13 |
| 1154.03 |
| 0.043 |
|
| 39 |
| 0.09 |
| 20.93 |
| 1126 |
| 0.043 |
|
| 39 |
| 0.09 |
| 20.85 |
| 1126 |
| 0.043 |
|
| 39 |
| 0.09 |
| 20.70 |
| 1124 |
| 0.043 |
|
| 39 |
| 0.09 |
| 20.5 |
| 1124 |
| 0.043 |
|
| 38 |
| 0.09 |
| 20.27 |
| 1124 |
| 0.043 |
|
| 38 |
| 0.09 |
| 20.22 |
| 1109.62 |
| 0.043 |
|
| 38 |
| 0.08 |
| 20.15 |
| 1042.78 |
| 0.043 |
|
| 38 |
| 0.08 |
| 20.08 |
| 1029.29 |
| 0.043 |
|
| 37 |
| 0.08 |
| 19.48 |
| 1026.18 |
| 0.043 |
|
| 37 |
| 0.08 |
| 19.43 |
| 979.36 |
| 0.043 |
|
| 37 |
| 0.08 |
| 19.23 |
| 891.35 |
| 0.043 |
|
| 37 |
| 0.08 |
| 19.23 |
| 883.81 |
| 0.043 |
DC: degree centrality; EC: eigenvector centrality; LAC: local average connectivity; BC: betweenness centrality; CC: closeness centrality.
Modules screened from the PPI network.
| Cluster | Score | Nodes | Edges | Node IDs |
|---|---|---|---|---|
| 1 | 27.357 | 29 | 383 | |
| 2 | 20.968 | 32 | 325 | |
| 3 | 9.692 | 27 | 126 | |
| 4 | 4.8 | 6 | 12 | |
| 5 | 4.4 | 16 | 33 |
PPI: protein–protein network.
Figure 4Modules extracted from the protein–protein interaction network. (A) module 1; (B) module 2; (C) module 3; (D) module 4; (E) module 5. Red, upregulated genes; green, downregulated genes.
Figure 5A ceRNA network among differentially expressed mRNAs, lncRNAs and miRNAs. Circle indicates the mRNAs; hexagon indicates the lncRNAs; triangle indicates the miRNAs; Red, upregulated genes; green, downregulated genes; blue, not differentially expressed. ceRNA, competing endogenous RNAs.
Potential drugs that reversed the expression of genes induced by nanoparticles.
| CMap Name | Mean | Enrichment | |
|---|---|---|---|
| 5182598 | −0.66 | −0.97 | 2.03 × 103 |
| Tocainide | −0.58 | −0.92 | 6.00 × 105 |
| NU-1025 | −0.38 | −0.88 | 2.88 × 102 |
| Harpagoside | −0.37 | −0.88 | 5.20 × 104 |
| Cloxacillin | −0.24 | −0.83 | 1.55 × 103 |
| Prestwick-1103 | −0.26 | −0.80 | 3.18 × 103 |
| Benzathine benzylpenicillin | −0.27 | −0.79 | 4.08 × 103 |
| Folic acid | −0.25 | −0.78 | 4.44 × 103 |
| Prestwick-967 | −0.50 | −0.77 | 5.61 × 103 |
| Timolol | −0.25 | −0.77 | 5.89 × 103 |
| Prestwick-675 | −0.26 | −0.77 | 6.15 × 103 |
| Indoprofen | −0.21 | −0.75 | 7.70 × 103 |
| Atractyloside | −0.33 | −0.71 | 4.45 × 103 |
| Arcaine | −0.41 | −0.69 | 2.01 × 102 |
| Retrorsine | −0.38 | −0.69 | 2.14 × 102 |
| Prestwick-689 | −0.38 | −0.68 | 2.32 × 102 |
| Fursultiamine | −0.51 | −0.67 | 2.72 × 102 |
| Isometheptene | −0.23 | −0.65 | 3.44 × 102 |
| Diphenylpyraline | −0.29 | −0.56 | 2.94 × 102 |
| Vincamine | −0.20 | −0.54 | 3.79 × 102 |
CMap: Connectivity Map.
Figure 6The target relationships between folic acid and genes. (A) the structure of folic acid; (B) the regulatory network between folic acid and genes. Red, upregulated genes.
Figure 7Validation of the expression levels of crucial genes in hypoxia/H2O2-induced retinal injury models. (A) GSE173233 dataset; (B) GSE151610 dataset; (C) GSE135844 dataset; (D) GSE122270 dataset. h, hour.